BRIEF published on 12/05/2024 at 13:05, 1 year 9 months ago Theralase Technologies Expands Bladder Cancer Study in Canada Canada Expansion Clinical Study Bladder Cancer Ruvidar Theralase Technologies
PRESS RELEASE published on 12/05/2024 at 13:00, 1 year 9 months ago Theralase(R) Launches New Clinical Study Site in Canada St. Joseph's Healthcare Hamilton joins Theralase®'s clinical investigation for bladder cancer treatment. Theralase® develops light-activated Ruvidar™ drug for BCG-Unresponsive NMIBC CIS patients Theralase® Bladder Cancer BCG-Unresponsive NMIBC CIS RuvidarTM Clinical Study Site
BRIEF published on 11/27/2024 at 23:10, 1 year 9 months ago Theralase Releases 3Q2024 Financial Overview Private Placements R&D Expenses Theralase Financial Overview Revenue And Margins Study II Results
PRESS RELEASE published on 11/27/2024 at 23:05, 1 year 9 months ago Theralase(R) Release’s 3Q2024 Financial Statements Theralase® Technologies Inc. releases unaudited financial statements for the nine-month period ended September 30, 2024, showcasing key financial and operational results. Conference call scheduled for December 4th Conference Call Financial Statements Operational Results Theralase® Technologies Inc. Study II
BRIEF published on 11/15/2024 at 13:05, 1 year 10 months ago Theralase Technologies Concludes Private Placement of $CAN 666,400 Private Placement Warrants Bladder Cancer Theralase Technologies Clinical Stage
PRESS RELEASE published on 11/15/2024 at 13:00, 1 year 10 months ago Theralase(R) Closes Non-Brokered Private Placement Theralase® Technologies Inc. successfully closes non-brokered private placement offering of units for cancer research and development funding Private Placement Offering Drug Development Clinical Study Cancer Research Theralase® Technologies Inc.
BRIEF published on 11/13/2024 at 00:28, 1 year 10 months ago Theralase Technologies Extends Warrant Expiry to 2027 TSX Venture Exchange Warrant Extension Cancer Treatment Theralase Technologies Pharmaceutical Development
PRESS RELEASE published on 11/13/2024 at 00:23, 1 year 10 months ago Theralase(R) Extends Warrants Theralase® Technologies Inc. intends to extend the expiry date of 1,000,000 share purchase warrants from Nov 17, 2024, to Nov 17, 2027. This extension is subject to TSXV approval TSX Venture Exchange Expiry Date Extension Theralase Technologies Inc. Share Purchase Warrants Clinical Stage Pharmaceutical Company
BRIEF published on 10/07/2024 at 13:05, 1 year 11 months ago Theralase Updates on Bladder Cancer Clinical Study FDA Approval Clinical Study Theralase Bladder Cancer Ruvidar
PRESS RELEASE published on 10/07/2024 at 13:00, 1 year 11 months ago Theralase(R) Provides Update on Bladder Cancer Clinical Study Theralase® Technologies Inc. provides update on bladder cancer clinical study for BCG-Unresponsive NMIBC CIS using Ruvidar™ drug activated by TLC-3200 Medical Laser System, achieving positive interim results Clinical Study Theralase® Bladder Cancer RuvidarTM BCG-Unresponsive
Published on 09/17/2026 at 14:31, 13 minutes ago First Breach Announces Three-Year Ammunition Supply and Distribution Agreement with SAS Ammo
Published on 09/17/2026 at 13:30, 1 hour 14 minutes ago UniDoc Health Equips San Juan, Puerto Rico Ambulances With Live Patient Video
Published on 09/17/2026 at 13:30, 1 hour 14 minutes ago Electric Royalties Reports Permitting Progress and New Exploration Results Across Critical Metals Royalty Portfolio
Published on 09/17/2026 at 13:00, 1 hour 44 minutes ago Organto Foods Strengthens Scalable European Operating Platform and Launches AI Powered Operational Transformation
Published on 09/17/2026 at 13:00, 1 hour 44 minutes ago Gold Terra Announces Fall Drilling with Three (3) Rigs Active on the Con Mine, Yellowknife, NWT
Published on 09/17/2026 at 14:35, 9 minutes ago Eightco Holdings (NASDAQ: ORBS) Reports Total Holdings of Approximately $380 Million, Includes OpenAI, Beast Industries, More Than 16,000 ETH and Nearly 302 Million WLD Tokens
Published on 09/17/2026 at 14:30, 14 minutes ago Hong Kong sets out strategic vision for developing the Northern Metropolis and creating a global talent hub
Published on 09/17/2026 at 13:25, 1 hour 18 minutes ago Custodian Property Income REIT plc: Results of Annual General Meeting
Published on 09/17/2026 at 13:25, 1 hour 19 minutes ago CDTL Highlights E-Drive + EMB Technologies for Commercial Vehicles at IAA Transportation 2026
Published on 09/17/2026 at 13:25, 1 hour 19 minutes ago ATOME PLC: Notice of Dispute and Intent to Submit Claim to Arbitration under the UK - Paraguay Bilateral Investment Treaty ("the Treaty" or "BIT")
Published on 09/16/2026 at 17:45, 20 hours 59 minutes ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 7 hours ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 20 hours ago Report on the Combined General Meeting of the 10th of September 2026
